Evidence map›Paper›PMID 20856821›Full record

ArticlePloS one2010

Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.

Sydney Rosen, Bruce Larson, Alana Brennan, Lawrence Long, Matthew Fox, Constance Mongwenyana, Mpefe Ketlhapile, Ian Sanne

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00270764 (Economic Outcomes of HIV/AIDS Care and Treatment in South Africa), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00270764 completednot on this map

Economic Outcomes of HIV/AIDS Care and Treatment in South Africa

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2005 to 2013Enrolled1,065ConditionsHIV Infections
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Interventions for improving employment outcomes for workers with HIV.The Cochrane database of systematic reviews · 2015
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Health Shocks and Natural Resource Management: Evidence from Western Kenya.Journal of environmental economics and management · 2015
    Article
  13. Article
  14. Article
  15. Massive benefits of antiretroviral therapy in Africa.The Journal of infectious diseases · 2014
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sydney RosenBoston University Center for Global Health and Development, Boston, Massachusetts, United States of America. sbrosen@bu.edu
Bruce Larson
Alana Brennan
Lawrence Long
Matthew Fox
Constance Mongwenyana
Mpefe Ketlhapile
Ian Sanne

Funding

Alabama Neuroscience Blueprint Core CenterP30NS057098 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROTH, KEVIN A · 2006 to 2010
$9.5M
Regulatory T Cells and Oncolytic Virotherapy of GliomaR01CA122930 · NCI · UNIVERSITY OF CHICAGO · PI LESNIAK, MACIEJ S · 2008 to 2015
$2.5M
Rates, Predictors and Mortality Impact of Losses from HIV Care in South AfricaK01AI083097 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FOX, MATTHEW ALEXANDER PEASE · 2009 to 2013
$615k
Developing an Adenoviral Vector Platform for Selective Gene Delivery to NeuronsF30NS065661 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, TRAVIS B. · 2009 to 2012
$143k
NCI NIH HHS R01 CA122930NCI NIH HHS R01CA122930NIAID NIH HHS K01 AI083097NIAID NIH HHS K01AI083097NINDS NIH HHS F30 NS065661NINDS NIH HHS F30NS065661NINDS NIH HHS NS057098NINDS NIH HHS P30 NS057098PHS HHS PEPFAR 13
6 · The paper itself

Abstract

backgroundAlthough the medical outcomes of antiretroviral therapy (ART) for HIV/AIDS are well described, less is known about how ART affects patients' economic activities and quality of life, especially after the first year on ART. We assessed symptom prevalence, general health, ability to perform normal activities, and employment status among adult antiretroviral therapy patients in South Africa over three full years following ART initiation. METHODOLOGY/PRINCIPAL

findingsA cohort of 855 adult pre-ART patients and patients on ART for <6 months was enrolled and interviewed an average of 4.4 times each during routine clinic visits for up to three years after treatment initiation using an instrument designed for the study. The probability of pain in the previous week fell from 74% before ART initiation to 32% after three years on ART, fatigue from 66% to 12%, nausea from 28% to 4%, and skin problems from 55% to 10%. The probability of not feeling well physically yesterday fell from 46% to 23%. Before starting ART, 39% of subjects reported not being able to perform their normal activities sometime during the previous week; after three years, this proportion fell to 10%. Employment rose from 27% to 42% of the cohort. Improvement in all outcomes was sustained over 3 years and for some outcomes increased in the second and third year. CONCLUSIONS/SIGNIFICANCE: Improvements in adult ART patients' symptom prevalence, general health, ability to perform normal activities, and employment status were large and were sustained through the first three years on treatment. These results suggest that some of the positive economic and social externalities anticipated as a result of large-scale treatment provision, such as increases in workforce participation and productivity and the ability of patients to carry on normal lives, may indeed be accruing.

Indexed as

Acquired Immunodeficiency SyndromeAdolescentAdultAnti-HIV AgentsCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedSouth AfricaTreatment OutcomeYoung AdultAnti-HIV Agents

Identifiers

PMID20856821
PMCPMC2939080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.